Isis Pharmaceuticals enters into agreement with Pfizer.
"This new agreement allows Isis to enhance Pfizer's in-house antisense program and aid an industry leader in uncovering the biological role of genes for future drug discovery," said Richard K. Brown, Ph.D., Isis' Vice President and GeneTrove President. "As a division of Isis, GeneTrove is a strategically important vehicle that encourages the industry's adoption and acceptance of antisense. We are pleased with the ongoing momentum the division has experienced over the last two years, and are delighted to put our antisense technology to work for Pfizer."
GeneTrove currently provides functional genomics services to Eli Lilly and Company, Celera Genomics, Abbott Laboratories, Amgen, Inc., Chiron Corporation, Merck & Co., Inc., Pharmacia Corporation, Johnson & Johnson, Aventis, and GlaxoSmithKline. In GeneTrove's Custom Target Validation collaborations, the division aids corporate partners in identifying the role of a specific gene (gene functionalization) and whether a specific gene is a good target for drug discovery (target validation).
Isis' functional genomics patent suite is comprised of approximately 50 patents and applications. Central components of the patent suite are intellectual property surrounding RNase H and second generation antisense inhibitors designed to work through the RNase H mechanism of action. RNase H is a common and potent mechanism of action employed by antisense when used as a functional genomics tool. The company's functional genomics suite of patents represents a subset of Isis' overall intellectual property estate of more than 1000 issued patents that Isis owns or exclusively licenses, covering RNA-based drug discovery and development.
Isis is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene (formivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 antisense products in its development pipeline, with two in late-stage development and six in Phase II human clinical trials. Affinitak (formerly called LY900003 and ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of more than 1000 issued patents worldwide. Isis' GeneTrove division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics is a division focused on the discovery of small molecule drugs that bind to RNA.
Isis Pharmaceuticals, Inc. +1-760-603-2521 www.isispharm.com
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Jan 1, 2003|
|Previous Article:||Cambridge Antibody to merge with Oxford Glycosciences.|
|Next Article:||Cell Genesys receives $15 million license fee from Transkaryotic Therapies.|
|Isis license functional genomics patents to atugen.|
|OncoGenex, Isis expand antisense anti-cancer drug collaboration.|
|Genzyme and Isis Form Alliance for High Risk Cardiovascular Patients.|